Loading
Heart Failure With Preserved Ejection Fraction (HFPEF) / Coronary Artery Disease / Iron Deficiency Anemia · Observational Study
ClinicalTrials.gov · August 7, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned non-interventional observational study registered on ClinicalTrials.gov with no results yet reported. The study aims to document the effects of Ferretab® Comp. (ferrous fumarate + folic acid) on hemoglobin level, cardiac symptoms, exercise tolerance, and safety in adults with iron deficiency anemia and cardiovascular disease over 12 weeks of routine clinical use. No efficacy or safety data are available from this registry record.
Observational. Iron Deficiency Anemia, Coronary Artery Disease, Heart Failure With Preserved Ejection Fraction (HFPEF); age from 18 Years. Intervention: Ferretab® comp.. n = 389. 5 sites: Russia.
This is a planned non-interventional observational study registered on ClinicalTrials.gov with no results yet reported. The study aims to document the effects of Ferretab® Comp. (ferrous fumarate + folic acid) on hemoglobin level, cardiac symptoms, exercise tolerance, and safety in adults with iron deficiency anemia and cardiovascular disease over 12 weeks of routine clinical use. No efficacy or safety data are available from this registry record.
No safety, tolerability, or efficacy outcome data are available; study completion and publication status unknown.
The source did not state who this applies to in practice.
This is a planned observational registry record with no results posted; it describes an intended non-interventional study in a specific population but carries no outcome data or efficacy evidence.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07753031). This is a study registration, not published results. Lead sponsor: Alcea. Recruitment status: NOT_YET_RECRUITING. Study type: OBSERVATIONAL. Enrollment: 389 participants (ESTIMATED). Conditions: Iron Deficiency Anemia, Coronary Artery Disease, Heart Failure With Preserved Ejection Fraction (HFPEF). Primary outcome measures: Absolute change in hemoglobin level at Week 12 , From baseline (before treatment with Ferretab® comp.) to 12 weeks after treatment initiation (Visit 2). Brief summary: The goal of this observational study is to learn how well Ferretab® comp. works and how safe it is for adults with iron deficiency anemia and cardiovascular disease who are receiving treatment as part of their usual medical care. The main questions it aims to answer are: * Does treatment with Ferretab® comp. improve anemia? * Does treatment with Ferretab® comp. improve heart-related symptoms, exercise tolerance, and overall well-being? * What side effects do participants have while taking Ferretab® comp.? This is a non-interventional study. Participants will receive Ferretab® comp. because their doctor has already decided to prescribe it as part of routine medical care. Ferretab® comp. is an oral medicine that contains iron (as iron fumarate) and folic acid. The study will not change their treatment. Participants will: * Take Ferretab® comp. for 12 weeks as prescribed by their doctor. * Attend study visits at the start of treatment, after about 4 weeks, and after about 12 weeks. * Have routine blood tests and health assessments during the study. * Report any side effects and record information in a patient diary. * Answer questions about their symptoms, exercise tolerance, and how easy the treatment is to use.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.